Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $15.3333.

COYA has been the subject of several research analyst reports. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Friday. Roth Mkm initiated coverage on shares of Coya Therapeutics in a research note on Friday, June 5th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, March 23rd. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Friday, April 10th.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new stake in shares of Coya Therapeutics in the third quarter valued at about $28,000. CIBC Private Wealth Group LLC purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $47,000. Occudo Quantitative Strategies LP purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $66,000. Lantern Wealth Advisors LLC purchased a new stake in shares of Coya Therapeutics in the third quarter valued at about $66,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $81,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Price Performance

NASDAQ COYA opened at $4.74 on Friday. Coya Therapeutics has a 1 year low of $3.71 and a 1 year high of $7.75. The company has a market capitalization of $111.20 million, a PE ratio of -4.12 and a beta of 0.62. The company has a fifty day moving average of $4.50 and a two-hundred day moving average of $4.85.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Coya Therapeutics had a negative net margin of 266.10% and a negative return on equity of 55.86%. The company had revenue of $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. On average, research analysts expect that Coya Therapeutics will post -1.49 earnings per share for the current year.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.